前列腺癌基金会扩容放射性药物智库 Orano Med、Telix与Siemens Healthineers加入 2026至2027年度议程在Vienna启动
Los Angeles——前列腺癌基金会（Prostate Cancer Foundation，PCF）10月17日宣布扩容其放射性药物智库（Radiopharmaceutical Think Tank），新增成员并确立2026至2027年度议程，聚焦加速新型放射性药物在癌症治疗中的研发与患者可及。智库第二年度计划与欧洲核医学会（EANM）年会同期公布，年会于10月17日至21日在奥地利 Vienna 举行。
新加入的成员包括 Orano Med、Telix Pharmaceuticals 与 Siemens Healthineers，与既有成员 Actithera、Advancell、Artbio、AstraZeneca、Bayer、Bicycle Therapeutics、Clarity Pharmaceuticals、Curium、Novartis 同列。智库自本月在 EANM 年会期间举行启动会起，新任期内共召开四次会议。
PCF 于2025年10月设立该智库，汇集产业、医学等领域的资深负责人，处理放射性药物研发与递送中的问题。第二年度的工作包括：识别并排序放射性药物研发与可及方面的障碍、向肿瘤学界与监管、支付方社区提出这些议题、推动解决方案，并把前列腺癌领域的经验推广至更多瘤种。
智库主席、Tulane University 医学院转化肿瘤研究项目主任 Oliver Sartor 表示，放射性药物领域的科学进展很快，开发与递送这些疗法的体系必须跟上，才能让各类癌症患者充分受益。PCF 执行副总裁兼首席医疗官 Phillip J. Koo 表示，放射性药物正在为前列腺癌治疗创造重要新机会，而要让其他癌症患者同样受益，需要多领域的专业与协作。
据 PCF 介绍，放射性药物已从传统的专科诊断工具，发展为癌症治疗的重要手段；PSMA 靶向放射配体疗法帮助确立了这一疗法在前列腺癌中的临床与商业潜力，相关研发正向更早病程与更多瘤种扩展。PCF 成立于1993年，累计筹款逾12亿美元，资助2,615个研究项目、312家癌症中心，足迹遍及29个国家。
Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase
LOS ANGELES — The Prostate Cancer Foundation (PCF) announced on October 17 the expansion of its Radiopharmaceutical Think Tank, adding new members and establishing its 2026-2027 agenda focused on accelerating development and patient access of novel radiopharmaceutical drugs for cancer treatment. PCF announced the second-year Think Tank program in conjunction with the European Association of Nuclear Medicine (EANM) Annual Congress, taking place October 17-21 in Vienna, Austria.
New Think Tank members for the 2026-2027 term include Orano Med, Telix Pharmaceuticals and Siemens Healthineers. They join existing members Actithera, Advancell, Artbio, AstraZeneca, Bayer, Bicycle Therapeutics, Clarity Pharmaceuticals, Curium and Novartis. Beginning with its kickoff meeting at the EANM Annual Congress this month, the Think Tank will convene four times during its new term.
PCF established the Radiopharmaceutical Think Tank in October 2025 to bring together senior leaders from industry, medicine and other disciplines. In its second year, the Think Tank will focus on identifying and prioritizing barriers to radiopharmaceutical development and access, bringing those issues to broader oncology, regulatory and payer communities, working toward potential solutions, and applying lessons from prostate cancer to radiopharmaceutical development across a variety of tumor types.
"The science around radiopharmaceuticals is moving quickly, and the systems needed to develop and deliver these therapies have to keep pace to optimize their benefits for patients across a broad range of cancers," said Oliver Sartor, M.D., Director of the Translational Oncology Research Program at Tulane University School of Medicine and Chair of the Radiopharmaceutical Think Tank. Phillip J. Koo, M.D., PCF's Executive Vice President and Chief Medical Officer, said radiopharmaceuticals are creating important new opportunities in prostate cancer treatment, and that realizing their full potential for patients with other cancers requires expertise and coordination from many different areas.
According to PCF, radiopharmaceuticals have moved beyond their traditional role in specialized diagnostics to become an increasingly important therapeutic approach in cancer care, with PSMA-targeted radioligand therapy helping establish the clinical and commercial potential of the approach in prostate cancer, while development continues across earlier stages of disease and other tumor types. Founded in 1993 by Mike Milken, PCF has raised more than $1.2 billion to fund more than 2,615 research projects at 312 leading cancer centers, with a global footprint spanning 29 countries.
发布：GSM·美国（发布链接）
图片来源：资料图：前列腺癌PSMA PET/CT影像（Rauscher等，《Cancer Imaging》2016，CC BY 4.0，via Wikimedia Commons）
GSM Global · 本篇英文版 English edition of this story
